

Name	: Mrs.REKHA GOYAI	L	Centre Details	:MALVIN DIAGNOSTICS
Age	: 37 Yrs Sex:	Female	Accession.ID	:SDL2411150041
Collection Date	: 15/Nov/2024 12:	51PM	Referred By	:DR GYNAE UNIT
Received Date	: 16/Nov/2024 09:	07AM	Report Date	:18/Nov/2024 01:30PM
Registration Date	: 15/Nov/2024		Ref.No/TRF.No	:/

DEPARTMENT OF CYTOLOGY

Conventional PAP Smear

Smear

SPECIMEN DETAILS :

LAB. NO. : C/6335/24

Conventional PAP smear One unstained smear.

CLINICAL DETAILS:

Cervix healthy.

REPORTING MODE :

By Bethesda System 2014

ADEQUACY:

Satisfactory for evaluation. Endocervical/transformation zone component absent.

MICROSCOPY :

Smear shows many intermediate cells, superficial squamous cells and moderate number of neutrophils.

IMPRESSION:

Negative for any intraepithelial lesion or malignancy.

Comment :

Retrospective case-control studies have failed to show an association between false-negative interpretations of specimens and lack of Endocervical cells (1,2). A recent Canadian review concluded that women should not be scheduled for early repeat testing because of lack of transformation zone sampling unless an abnormality was suspected (3,4).

1. Mitchell H, Medley G. Differences between Papanicolaou smears with correct and incorrect diagnoses. Cytopathology. 1995;6:368-75.

2. O'Sullivan JP, A'Hern RP, Chapman PA, Jenkins L, Smith R, al-Nafussi A, et al. A case-control study of true-positive versus false-negative cervical smears in women with cervical intraepithelial neoplasia (CIN) III. Cytopathology.1998;9:155-61.

3. Elumir-Tanner L. Doraty M. Management of Papanicolaou test results that lack endocervical cells. Can Med Assoc J. 2011;183:563-8.

4. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Low Genit Tract Dis. 2013;17:S1-27.

DISCLAIMER

Gynaecological cytology is a screening test that aids in the detection of cervical cancer and cancer precursors. Both false positive and false negative results can occur. The test should be used at regular intervals, and positive results should be confirmed before definitive therapy.



Dr. Archana Sharma MBBS, MD, PDCC Liver Pathology Consultant Surgical Pathology DMC RG- No.64610

Verify this report by scanning the QR code on top. In case of any discrepancy please report to +0124 665 0000 This sample is processed at **Oncquest Laboratories Ltd.; A-17 Infocity, Sector-34, Gurugram**



Name	: Mrs.REKHA GC)YAL	Centre Details	:MALVIN DIAGNOSTICS
Age	: 37 Yrs S	ex: Female	Accession.ID	:SDL2411150041
Collection Date	: 15/Nov/2024	12:51PM	Referred By	:DR GYNAE UNIT
Received Date	: 16/Nov/2024	09:07AM	Report Date	:18/Nov/2024 01:30PM
Registration Date	: 15/Nov/2024		Ref.No/TRF.No	:/

DEPARTMENT OF CYTOLOGY

*** End Of Report ***

Disclaimer: All Results released pertain to the specimen submitted to the lab

1. Test results are dependent on the quality of the sample received by the lab

2. Tests are performed as per schedule given in the test listing and in any unforeseen circumstances, report delivery may be delayed

3. Test results may show interlaboratory variations


4. All dispute and claims are subjected to local jurisdiction only. Clinical correlation advised.

5. Test results are not valid for medico legal purposes

6. For all queries, feedbacks, suggestions, and complaints, please contact customer care support +0124 665 0000



Dr. Archana Sharma MBBS , MD, PDCC Liver Pathology Consultant Surgical Pathology DMC RG- No.64610



67/1, New Rohtak Road. New Delhi-110 005 (India) Tel.: 47774141, 9212167895 E-mail.: info@jmh.in Website : www.jmh.in

JMH/03/24/4000PCS/PP

F.No.: 74

JEE WAN MAL HOSPI Tradition of Trust & Care Since 1	TAL	· · ·	
	ug Goyal		
Deptt	Ref by	Date	15/11/24
M.R. No	0 0,	//N	L L
Deptt. of General & Laparos	copic Surgery		
Dr. Vinay Sabharwal M.B.B.S., M.S., FICA Hon. Surgeon to Fmr. President of India Sir Ganga Ram Hospital Sr. Member : Assciaciation of Surgeons of Indi Indian Association of Gastro. Endo Surgeons Indian Hernia Society Association of Min. Access Surgeons of India E-mail: drvinay@jmh.in Website: www.drvinay@sabharwal.com DMC No. 4687	a 070 LIS Dela	altor: lest-rin	CA to Shy bi you age Z. chicken Pox tsy back.
Dr. Malvika Sabharwal MBBS, DGO, F.I.C.O.G., Dipl. Endo. Surgery (I Awarded Padmashri by the President of Indi Chief Dept. of Gynae, Laparoscopic, Endosc President, Delhi Gynae Endoscopy Society (Founder Chairperson: Indian Ass. of Gynae. I International Society of Gynae. Laparoscopy Federation of obst. & Gynae. Laparoscopy Federation of obst. & Gynae. Societies of India International College of Obst. & Gynae E-mail: drmalvika@jmh.in Website: drmalvika@sabharwal.com DMC No. 4686	(2018)	Folslæslig alau A	18 yr Daels, -1
Deptt. of E.N.T.	6 ·		RAA
Dr. R.K. Trivedi M.B.B.S., D.L.O., M.S. (E.N.T.) Senior Consultant D.M.C. No.: 12647	ornee hazy	Eco-Teas	s APA ap duff
Dr. Rajeev Nangia M.B.B.S., M.S. (E.N.T.) Senior Endoscopic Surgeon DMC No. 4681		I Owell	hr. D
Deptt. of Ophthalmology			, U
Dr. Ashwani Seth M.B.B.S., M.S. Senior Consultant Eye Surgeon D.M.C. No.: 13702		A	
Dr. S.C. Pahwa M.B.B.S., M.S. (Ophth) Eye Surgeon D.M.C. No.: 8424		DR. S.C. PAH	Dethi)
Deptt. of Dentistry		EYE Specialist	4
Dr. Varun Aggarwal B.D.S., M.D.S., CAIC, M.I.D.A. Consultant Implantologist & Unit Head		Jeewan Mala H New Delhi-110	105010
Dr. Neha Gupta B.D.S., PGCHM, F.I.C.D., M.I.D.A. Senior Consultant Deptt. of Dentistry			

F.No.: 72

/1, New Rohtak Road. New Delhi-110 005 (India) Tel.: 47774141, 92121678 E-mail.: Info@jmh.in Website : www.jmh.in. www.gynaeendoscopy.in

JMH/05/24/4000PCS/PP

GYNAE DEPARTMENT Mark of Excellence JEEWAN M VASANT VIHAR CLINIC JEEWAN MALA HOSP!TAL NEW ROHTAK ROAD E-87, PASCHIM MARG HOSPITAL VASANT VIHAR 9212150582, 9212150586 Tradition of Trust & Care Since 1920 9212526855 For Appointment call (8 am HM1. OPD ASSESSMENT FORM GYNAE DEPTT. 9212150582 (Gyn. & Obs.) 9212150586 For Appt. 9212526855 Time 8 AM to 8 PM F).....Date/Time :..... Age/Sex. 37 Name of Patient. ynae und Name of Doctor for Routine health up. Presenting complaints : It is visuelly impared History of presenting complaints : M/H= 3/25-26 dys Menstrual History : LMP EDD : 12/2 - 1stal fresh-Ggsace Hop Includ fresh - 3ysace jaip) Marital History : **Obstetric History :** Past history / surgical procedures : Ho of ? Olemore Concernin Molles. (Endomelnil, ? Cernil) survivn; taken Chemot RT. Pedal edema Pulse Weight..... Weight..... gl- pet is ver en coofendere. Cr-péapeut os paps'snun fakas Sover taken Location : 1. P/A 2. P/S 3. P/V STNS, DV.

Treatment • Investigation JNH) T. CCH-1 Lab OD T. Upme B. - 1 Lab week gx/ 12 who for a Repair 12 who 15/11/24 Adv. liver @ grade ? fatz lur; Upper Ab@. Unis A/v @ ET:- 6.3mm both ovaries (10); B/L, Advere - der horizolar ploativ :411 11 - 119 Eddine VNY13 Liquid Other Soft Diet Normal Uncapartic Signature & Name of the Doctor her fred JMH/06/19/3000PCS/PP F.No.-70 87.7 NS. P/v. all the sec ø



Mark of Excellence



'Rekha Mrs Date: November 15, 2024

Age: 37 Y/ Sex: F MR No:- 37239

ULTRASOUND WHOLE ABDOMEN

Liver is normal in size and shows diffuse increase in echogenicity s/o grade-I fatty infiltration.

Intrahepatic bile ducts and portal radicals are normal in caliber. Portal vein is normal in caliber

Gall bladder does not show any evidence of cholecystitis or cholelithiasis.

- Calculus Absent
- Sludge Absent .
- Wall edema;- Absent. .
- Wall thickness:- Normal 1.
- Pericholecystic adhesions:- Absent
- CBD- proximal visualized part: is not dilated.
- CBD- Mid and distal segment is obscured due to technical limitation.
- Central IHBR:- normal in caliber.

Both kidneys are of normal size, shape and echopattern. No calculus, growth or hydronephrotic changes seen in either kidney. The parenchymal thickness is normal & cortico-medullary differentiation is well maintained.

Spleen is normal in size and echotexture. Pancreas does not show any pathology.

Urinary bladder is distended and shows no mural or intraluminal pathology. Uterus is anteverted and higher up in pelvis, normal in size, shape and echopattern. Endometrium echo is 6.3 mm Both the ovaries appear normal in size, shape, and echopattern. Bilateral adnexae are clear. No adnexal mass. No free fluid or pelvic collection seen.

Please correlate clinically.


DR. GLOSSY B SABHARWAL, MD CONSULTANT RADIOLOGIST \This report is only a professional opinion and it is not valid for medico-legal purposes.

JEEWAN MALA HOSPITAL PVT. LTD.

67/1, New Rohtak Road, New Delhi-110 005 (India) Tel. : 47774141, 9212167895 E-mail : info@jmh.in Website : www.jmh.in GSTIN No. 07AABCJ0920A1ZD / CIN No. U74899DL1991PTC043833

JMH/09/24/10000PCS/PP

F.No.- 103







Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 01:04 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range	
	HAEMAT	OLOGY		
Complete Haemogram - Hb RBC count an	d indices, TLC,	DLC, PLATELET,	ESR.	
Hemoglobin (Hb)	12.4	g/dL	12.0 - 15.0	
Method : Whole Blood, SLS-haemoglobin				
Erythrocyte (RBC) Count	3.94	x 10^6/uL	3.8 - 4.8	
Method : Whole Blood, DC detection				
HCT	38.7	%	36 - 46	
Method : Whole Blood, RBC pulse height detection				
Mean Cell Volume (MCV)	98.2	fL	83 - 101	
Method : Whole Blood, Electrical Impedence				
Mean Cell Haemoglobin (MCH)	31.5	pg	27 - 32	
Method : Whole Blood, Calculated				
Mean Corpuscular Hb Concn. (MCHC)	32.0	g/dL	32.0 - 35.0	
Method : Whole Blood, Calculated				
Red Cell Distribution Width (RDW) CV	14.1	%	11.6 - 14.0	
Method : Whole Blood, Calculated				
Total Leucocytes (WBC) Count	6.3	x 10^3 /uL	4 - 10	
Method : Whole Blood, Flow cytometry				
DLC (Differential Leucocytes Count)				
Neutrophils	51.9	%	40 - 80	
Method : Whole Blood, Fluorescence /Flowcytometry/				
Microscopy				
Lymphocytes	37.8	%	20 - 40	
Method : Whole Blood, Fluorescence /Flowcytometry/				
Microscopy	5.1	%	2 - 10	
Monocytes	5.1	70	2 - 10	
Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy				
Eosinophils	4.9	%	1 - 6	
Method : Whole Blood, Fluorescence /Flowcytometry/		,		
Microscopy				
Basophils	0.3	%	0 - 2	
Method : Whole Blood, Fluorescence /Flowcytometry/				
Microscopy				
Absolute Neutrophil Count	3.27	x 10^3/uL	2.0 - 7.0	
Method : Whole Blood, Calculated				
Absolute Lymphocyte Count	2.38	x 10^3/uL	1 - 3	
Method : Whole Blood, Calculated				



Referred By : ARCOFEMI HEALTH CARE

Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 01:04 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
Absolute Monocyte Count	0.32	x 10^3u/L	0.2-1.0
Method : Whole Blood, Calculated			
Absolute Eosinophil Count	0.31	x 10^3/uL	0.02 - 0.5
Method : Whole Blood, Calculated			
Absolute Basophils Count	0.02	x 10^3/uL	0.02 - 0.1
Method : Whole Blood, Calculated			
Platelet Count	120	x 10^3/uL	150 - 410
Method : Whole Blood, DC Detection			
ESR - Erythrocyte Sedimentation Rate	22	mm/hr	<20
Method : Whole blood , Modified Westergren Method			

Interpretation:

It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever,. It is also increased in multiple myeloma, hypothyroidism.

Tests done on Automated Six Part Cell Counter.

END OF REPORT

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012



Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
	IMMUN	DLOGY	
T3, T4, TSH (Thyroid Profile Total),Serum			
(Triiodothyronine) T3-Total	0.8	ng/mL	0.80 - 2.00
Method : ECLIA (Thyroxine) T4-Total	5.81	ug/dL	5.10 - 14.10
Method : ECLIA			
TSH-Ultrasensitive Method : ECLIA	1.51	ulU/mL	0.27-4.20
Interpretation			
The Biological reference interval provided is for Adults.			

For age specific reference interval, please refer to the table given below.

TSH	T3/FT3	T4/FT4	Interpretation
High	Normal	Normal	Subclinical Hypothyroidism
Low	Normal	Normal	Subclinical Hyperthyroidism
High	High	High	Secondary Hypothyroidism
LOW	High/Normal	High/Normal	Hyperthyroidism
Low	Low	Low	Non Thyroidal illness/Secondary Hyperthyroidism

TSH (mU/mL)

	New Born	0.7	15.2
	6 days - 3 Months	0.72	11
Childern	4 -12 Months	0.73	8.35
onidoni	1-6 Years	0.7	5.97
	7-11 Years	0.6	4.84
	12-20 years	051	4.3
Adults		0.27	4.20

TSH levels are subjected to circadian variation, rising several hours before the onset of sleep, reaching peak levels between 11 pm and 6 am. Nadir concentration are

observed during the afternoon. diurnal variation in TSH levels is approx 50%+/-, hence time of the day can influence the measured serum concentration.

END OF REPORT

66A/3, Pal Mohan Bhawan, New Rohtak Road, New Deihi-110005 Phone: 011-47774391, 9810621005 Email: reports@malvindiagnostics.com Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.

Technology partners



Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012





Patient Name : MRS. REKHA GOYAL Age / Gender : 37 years / Female Receiving Time : Nov 15, 2024, 10:59 a.m. MR No. / IPD No. : / Reporting Time : Nov 15, 2024, 12:47 p.m. Patient Type / Bed No. : I / Referred By : ARCOFEMI HEALTH CARE Panel : Dr Arcofemi Health Care PVT.limited (PVT.LIMITED (MEDIWHEEL) MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL) **Test Description** Value(s) Unit(s) **Reference Range** HAEMATOLOGY **Blood Group (ABO)** Blood Group "A" Method : Forward and Reverse by Slide method Positive **RH** Factor Methodology This is done by forward and reverse grouping by slide agglutination method. Interpretation Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B

antigen expression and the isoagglutinins are fully developed (2-4 years).

END OF REPORT

Dr.Arti Tripathi

MD Pathology Chief Consultant, Pathology DMC No: 43012

66A/3, Pal Mohan Bhawan, New Rohtak Road, New Deihi-110005 Phone: 011-47774391, 9810621005 Email: reports@malvindiagnostics.com Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.

Page 5 of 14

Registration Time : Nov 15, 2024, 10:59 a.m.





Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
	BIOCHEI	MISTRY	
LFT (Liver Function Test,Serum)			
Total Protein	7.8	g/dL	6.4-8.3
Method : Biuret Method			
Albumin	4.5	g/dL	3.5 - 5.2
Method : Bromocresol Green			
Globulin	3.30	g/dL	1.8 - 3.6
Method : Calculated			
A/G Ratio	1.36	ratio	1.2 - 2.2
Method : Calculated			
SGOT	24	U/L	0 to 32
Method : IFCC without Pyridoxal Phosphate			
SGPT	21	U/L	0 to 33
Method : IFCC without Pyridoxal Phosphate			
Alkaline Phosphatase-ALP	88	U/L	35-104
Method : PNP AMP Kinetic			
GGT-Gamma Glutamyl Transferase	10	U/L	0 to 40
Method : IFCC			
Bilirubin Total	0.50	mg/dL	0.0-0.90
Method : Colorimetric Diazo Method			
Bilirubin - Direct	0.10	mg/dL	Adults and Children: < 0.30
Method : Colorimetric Diazo Method			
Bilirubin - Indirect	0.40	mg/dL	0.1 - 1.0
Method : Calculated			

Interpretation :

SGOT/ SGPT: Increased in Acute viral hepatitis, Biliary tract obstruction (cholangitis, choledocholithiasis), Alcoholic hepatitis and Cirrhosis, liver abscess, metastatic or primary liver cancer; non-alcoholic steatohepatitis; right heart failure. Decreased in Pyridoxine (vit B6) deficiency.

Alkaline Phosphatase: Increased in Obstructive hepatobiliary disease, Bone disease (physiologic bone growth, Paget disease, Osteomalacia, Osteogenic sarcoma, Bone metastases), Hyperparathyroidism, Rickets, Pregnancy (third trimester). Decreased in Hypophosphatasia.

GGT: Increased in Liver disease Acute viral or toxic hepatitis, Chronic or subacute hepatitis, Alcoholic hepatitis, Cirrhosis, Biliary tract obstruction.

Protein: Moderate-to-marked hyperproteinemia maybe due to multiple myeloma and other malignant paraproteinemias, Hypoproteinemia may be due to decreased production or increased protein loss.

Albumin: Increased in Dehydration, Shock, Hemoconcentration. Decreased in hepatic synthesis(Chronic liver disease, malnutrition, malabsorption, malignancy), Increased losses (Nephrotic syndrome, Burns, Trauma, Hemorrhage with fluid replacement, acute or chronic glomerulonephritis), Hemodilution (pregnancy, CHF) and Drugs (estrogens). Bilirubin: A substance produced during the normal breakdown of red blood cells. Elevated levels of bilirubin (jaundice) might indicate liver damage or disease or certain types of anemia.

66A/3, Pal Mohan Bhawan, New Rohtak Road, New Deihi-110005 Phone: 011-47774391, 9810621005 Email: reports@malvindiagnostics.com Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.

Technology partners are DR. GAUR PATH LAB





Patient Name : MRS. REKHA GOYAL Registration Time : Nov 15, 2024, 10:59 a.m. Age / Gender : 37 years / Female Receiving Time : Nov 15, 2024, 10:59 a.m. MR No. / IPD No. : / Reporting Time : Nov 15, 2024, 12:47 p.m. Patient Type / Bed No. : | / Referred By : ARCOFEMI HEALTH CARE Panel : Dr Arcofemi Health Care PVT.limited (PVT.LIMITED (MEDIWHEEL) MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL) **Test Description** Value(s) Unit(s) **Reference Range**

END OF REPORT

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012





Referred By : ARCOFEMI HEALTH CARE

Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
	BIOCHE	MISTRY	
KFT (Renal Function Test,Serum)			
Urea	21.4	mg/dL	16.6-48.5
Method : kinetic (urease-GLDH)			
BUN	10.00	mg/dL	6-20
Method : Calculated			
Creatinine	0.70	mg/dL	0.30-1.10
Method : Kinetic Colorimetric (Jaffe Method)			
Uric Acid	4.6	mg/dL	2.4-5.7
Method : Enzymatic Colorimetric: Uricase-POD			
Interpretation :			

Urea:- Increased in renal diseases, urinary obstructions, shock, congestive heart failure .Decreased in liver failure and pregnancy.

Creatinine :- Elevated in renal dysfunction, reduced renal blood flow shock, dehydration, Congestive heart failure, Diabetes Acromegaly. Decreased levels are found in Muscular Dystrophy.

Uric acid:- Increased in Gout, Arthiritis, impaired renal functions and starvation. Decreased in Wilson's disease, Fanconis Syndrome and Yellow Atrophy of Liver.

Sodium:-Increased in Excessive dietary salt ,Diuretic therapy,Adrenal insufficiency,Salt-wasting nephropathy and Vomiting.Decreased levels are seen in Hyperaldsteronism ,Hyponatremia,Prerenal Azotemia,Renal Failure and Glomerulonephritis.

Potassium:- Low levels is common in vomiting, diarrhea, alcoholism, and folic acid deficiency. Increase level are seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid potassium infusion.

Chloride:- Increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis, diabetes insipidus, adrenocortical hyperfuction. Decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis.

END OF REPORT

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012





Referred By : ARCOFEMI HEALTH CARE

Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

able: <= 200 erline High: 201-239 > 239 The National Cholesterol ation Program (NCEP) Adult ment Panel III Report.
erline High: 201-239 > 239 The National Cholesterol ation Program (NCEP) Adult ment Panel III Report.
erline High: 201-239 > 239 The National Cholesterol ation Program (NCEP) Adult ment Panel III Report.
> 239 The National Cholesterol ation Program (NCEP) Adult ment Panel III Report.
The National Cholesterol ation Program (NCEP) Adult ment Panel III Report.
ation Program (NCEP) Adult ment Panel III Report.
ment Panel III Report. ■■■■ al: < 150
al: < 150
erline High: 150-199
200-499
High: >= 500
sk - >65 mg/dL
rate risk - 45-65 mg/dL
risk - < 45 mg/dL
nal: < 100
optimal/above optimal: 100-129
erline high: 130-159
160-189
High: >= 190
able: < 130 mg/dL
erline High: 130-159mg/dL
160-189 mg/dL
High: > or = 190 mg/dL
5.0
able / low risk - 0.5 -3.0
Moderate risk - 3.0- 6.0
ted / High risk - > 6.0
able / low risk - 0.5 -3.0
Moderate risk - 3.0- 6.0
ted / High risk - > 6.0

Note: 10-12 hours fasting sample is required.

66A/3, Pal Mohan Bhawan, New Rohtak Road, New Delhi-110005 Phone: 011-47774391, 9810621005 Email: reports@maivindiagnostics.com Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.

Technology partners





Patient Name : MRS. REKHA GOYAL Registration Time : Nov 15, 2024, 10:59 a.m. Age / Gender : 37 years / Female Receiving Time : Nov 15, 2024, 10:59 a.m. MR No. / IPD No. : / Reporting Time : Nov 15, 2024, 12:47 p.m. Patient Type / Bed No. : | / Referred By : ARCOFEMI HEALTH CARE Panel : Dr Arcofemi Health Care PVT.limited (PVT.LIMITED (MEDIWHEEL) MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL) **Test Description** Value(s) Unit(s) **Reference Range**

END OF REPORT

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012

> 66A/3, Pal Mohan Bhawan, New Rohtak Road, New Delhi-110005 Phone: 011-47774391, 9810621005 Email: reports@malvindiagnostics.com Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.



Page 10 of 14



Referred By : ARCOFEMI HEALTH CARE

Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
	BIOCHE	MISTRY	
Glucose (Fasting)			
Glucose Fasting	107	mg/dL	Normal: 72-106
Method : Plasma, Enzymatic Hexokinase			Impaired Tolerance: 100-125
			Diabetes mellitus: >= 126
			(on more than one occassion)
			(American diabetes association
			guidelines 2018)

Interpretation

Glucose is the major carbohydrate present in the peripheral blood. Oxidation of glucose is the major source of cellular energy in the body. The concentration of glucose in blood is controlled within the narrow limits by many hormones, the most important of which are produced by the pancreas. The most frequent cause of hyperglycaemia is diabetes mellitus resulting from deficiency in insulin secretion or action. These include pancreatitis, thyroid dysfunction, renal failure, and liver disease. Hypoglycaemia is less frequently observed. A variety of conditions may cause low blood glucose levels such as insulinoma, hypopituitarism, or insulin induced hypoglycaemia.

END OF REPORT

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012





Age / Gender : 37 years / Female Receiving Time : Nov 15, 2024, 10:59 a.m. MR No. / IPD No. : / Reporting Time : Nov 15, 2024, 03:46 p.m. Patient Type / Bed No. : I / Referred By : ARCOFEMI HEALTH CARE Panel : Dr Arcofemi Health Care PVT.limited (PVT.LIMITED (MEDIWHEEL) MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL) **Test Description** Value(s) Unit(s) **Reference Range** BIOCHEMISTRY Glycated Hb (HbA1c) 5.3 Non-Diabetic HbA1c (Glycated Hemoglobin) % : <5.7 Method : EDTA Whole blood, HPLC, NGSP certified Pre Diabetes : 5.7 - 6.4 Diabetes : ≥ 6.5 **Estimated Average Glucose :** 105.41 mg/dL Interpretations • HbA1c has been used as one of the key biomarkers in identifying patients with Diabetes . American Diabetes Association (ADA) and several clinical groups have endorsed utility of HbA1c testing using a cut off value of 6.5%. The average concentration of blood

Registration Time : Nov 15, 2024, 10:59 a.m.

glucose(eBG) is reflected in this test over a period of the past three months.

Therapectic goals for monitoring Diabetes.

Goal of therapy < 7% HbA1c.

Action suggested > 8 % HbA1c

• Patients with shortened red cell survival(hemolytic disease), recent significant blood loss have lower HbA1c values .

High HbA1c is associated with Iron deficiency ,patients with polycythemia or post splenctomy.

Note : The presence of hemoglobin variants can interfere with measurment of HbA1c.

END OF REPORT

Dr.Arti Tripathi **MD** Pathology Chief Consultant, Pathology DMC No: 43012





Referred By : ARCOFEMI HEALTH CARE

Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range	
	CLINICAL PA	ATHOLOGY		
Urine (RE/ME)				
Physical Examination :				
Volume	40		mL	
Method : Visual Observation				
Colour	Pale Yellow		Pale Yellow	
Method : Visual Observation				
Transparency (Appearance)	Clear		Clear	
Method : Visual Observation				
Deposit	Absent		Absent	
Method : Visual Observation				
Reaction (pH)	6.0		4.5 - 8.0	
Method : Double Indicator method				
Specific Gravity	1.015		1.010 - 1.030	
Method : Ionic Concentration				
Chemical Examination (Dipstick Metho	od) Urine			
Urine Protein	Absent		Absent	
Method : Protein Ionisation/ Manual				
Urine Glucose (sugar)	Absent		Absent	
Method : Oxidase Reaction/ Manual				
Blood (Urine)	Absent		Absent	
Method : Peroxidase Reaction				
Microscopic Examination Urine				
Pus Cells (WBCs)	1 - 2	/hpf	0 - 5	
Method : Microscopy				
Epithelial Cells	1 - 2	/hpf	0 - 4	
Method : Microscopy				
Red blood Cells	Absent	/hpf	Absent	
Method : Microscopy				
Crystals	Absent		Absent	
Method : Microscopy				
Cast	Absent		Absent	
Method : Microscopy	••			
Yeast Cells	Absent		Absent	
Method : Microscopy	A 1 .		.	
Amorphous Material	Absent		Absent	
Method : Microscopy				

66A/3, Pal Mohan Bhawan, New Rohtak Road, New Delhi-110005 Phone: 011-47774391, 9810621005 Email: reports@malvindiagnostics.com Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.

Technology partners org DR. GAUR PATH LAB



Referred By : ARCOFEMI HEALTH CARE

Age / Gender : 37 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : | /

PVT.LIMITED (MEDIWHEEL)



Registration Time : Nov 15, 2024, 10:59 a.m.

Receiving Time : Nov 15, 2024, 10:59 a.m.

Reporting Time : Nov 15, 2024, 12:47 p.m.



Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range	
Bacteria	Absent		Absent	
Method : Microscopy				
Others	Absent			

Remarks:-

Epithelial cells	Urolithiasis bladder carcinoma or hydronephrosis ,ureteric stents or bladdercatheters for prolonged periods of time.	
Granular casts	Low intratubular pH,high urine osmolality and sodium concentration, interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration,acute congestive heart failure, renal diseases.	
Calcium Oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of VitaminC, the use of vascodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit(A verrhoa carambola)or its juice	
Uric acid	Artharitis	
Bacteria	Urinary infection when present in significant numbers and with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

END OF REPORT

Dr.Arti Tripathi MD Pathology Chief Consultant, Pathology DMC No: 43012

